Blue Trust Inc. Has $54,000 Stake in DaVita Inc. (NYSE:DVA)

Blue Trust Inc. grew its holdings in DaVita Inc. (NYSE:DVA) by 56.4% during the third quarter, Holdings Channel.com reports. The firm owned 330 shares of the company’s stock after acquiring an additional 119 shares during the period. Blue Trust Inc.’s holdings in DaVita were worth $54,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in DaVita by 1.6% during the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 134,823 shares of the company’s stock worth $18,612,000 after acquiring an additional 2,129 shares during the last quarter. First Trust Direct Indexing L.P. increased its holdings in shares of DaVita by 3.9% in the first quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock valued at $358,000 after purchasing an additional 98 shares in the last quarter. Janney Montgomery Scott LLC raised its position in DaVita by 175.5% in the 1st quarter. Janney Montgomery Scott LLC now owns 18,937 shares of the company’s stock worth $2,614,000 after purchasing an additional 12,064 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new position in DaVita during the 1st quarter worth $2,899,000. Finally, Tokio Marine Asset Management Co. Ltd. boosted its position in DaVita by 11.9% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,377 shares of the company’s stock valued at $328,000 after buying an additional 253 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Truist Financial boosted their target price on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Barclays upped their target price on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday. TD Cowen lifted their price target on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Bank of America boosted their price target on shares of DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Finally, UBS Group raised their price target on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $161.80.

DaVita Stock Performance

Shares of DVA opened at $139.81 on Friday. The firm’s 50 day moving average price is $157.96 and its two-hundred day moving average price is $145.97. The company has a debt-to-equity ratio of 9.94, a quick ratio of 1.12 and a current ratio of 1.16. DaVita Inc. has a twelve month low of $76.17 and a twelve month high of $168.50. The firm has a market cap of $11.73 billion, a P/E ratio of 14.89, a PEG ratio of 0.90 and a beta of 0.87.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 77.00% and a net margin of 6.86%. DaVita’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the company posted $2.85 EPS. On average, analysts forecast that DaVita Inc. will post 9.99 EPS for the current fiscal year.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the transaction, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, CEO Javier Rodriguez sold 50,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $165.05, for a total transaction of $8,252,500.00. Following the sale, the chief executive officer now owns 837,835 shares in the company, valued at approximately $138,284,666.75. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Kathleen Alyce Waters sold 7,857 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now directly owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 173,482 shares of company stock valued at $27,387,069. 2.00% of the stock is owned by insiders.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.